BNTX BioNTech

Watchlist

119.830
-2.950-2.40%

Close Feb 14 16:00 ET

119.830
0.0000.00%

Post 20:01 ET

28.73BMarket Cap-58.88P/E (TTM)

About BioNTech Company

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Company Profile

SymbolBNTX

Company NameBioNTech

Listing DateOct 10, 2019

Issue Price15.00

Founded2008

CEOProfessor Ugur Sahin, M.D.

MarketNASDAQ

Employees6133

Securities TypeDR

ADS Ratio1.0 : 1.0

Fiscal Year Ends12-31

AddressAn der Goldgrube 12

CityMainz

ProvinceRheinland-Pfalz

CountryGermany

Zip Code55131

Phone49-6131-9084-0

Websitehttp://www.biontech.de

Company Executives

Name
Position
Salary

Professor Ugur Sahin, M.D.
Chief Executive Officer
3.06M

Jens Holstein
Chief Financial Officer
1.32M

Dr. Sierk Poetting, PhD
Chief Operating Officer
821.00K

Dr. Ozlem Tureci, M.D.
Chief Medical Officer
814.00K

James Ryan, PhD
Chief Legal Officer
--

Ryan Richardson
Chief Strategy Officer
1.41M

Helmut Jeggle
Chairman of the Supervisory Board
226.00K

Dr. Ulrich Wandschneider, PhD
Deputy Chairman of the Supervisory Board
114.00K

Michael Motschmann
Member of the Supervisory Board
80.00K

Baroness Nicola Blackwood
Member of the Supervisory Board
46.00K

Professor Anja Morawietz, PhD
Member of the Supervisory Board
105.00K

Professor Rudolf Staudigl, PhD
Member of the Supervisory Board
90.00K

BNTX BioNTech

About BioNTech Company

Company Profile

Company Executives

Trending Stocks